2023-08-08 09:00:05 ET
- Madrigal Pharmaceuticals press release ( NASDAQ: MDGL ): Q2 GAAP EPS of -$4.69.
- As of June 30, 2023, Madrigal had cash, cash equivalents and marketable securities of $298.4 million, compared to $358.8 million at December 31, 2022.
-
Interest income for the three and six month periods ended June 30, 2023 was $3.6 million and $7.3 million, compared to $0.3 million and $0.4 million in the comparable prior year periods. The increase in interest income was due primarily to a higher average interest rate in 2023.
For further details see:
Madrigal Pharmaceuticals GAAP EPS of -$4.69